Chimerasome is based on a single protein that can be assembled to form a spherical protein nanocage encapsulating drugs or nucleic acid therapeutics.
It can be decorated with antibodies or peptides externally, enabling highly specific cellular targeting of the payload.
Both the companies have not disclosed the financial terms of the agreement.
Sevion Therapeutics CEO Ronald Martell said: "The Chimerasome biologics approach allows for specific optimization of regions of the building block responsible for the key functions required for a successful delivery system, including serum stability, triggered opening and payload release, tunable PK and biodistribution, as well as safety.
"This collaboration is a key example of our effort to leverage our pipeline and platforms through partnership, while we look to advance our internal antibody pipeline and explore in-licensing opportunities."
Sevion discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases. The compny’s product candidates are derived from multiple technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages.